Overview
| Product name | Recombinant Human DLL1 Protein |
|---|
| Catalog No. | RP02151 |
|---|
| Description | Recombinant Human DLL1 Protein is produced by Mammalian expression system. The target protein is expressed with sequence (Gln18-Gly540) of human DLL1 (Accession #O00548) fused with a 6xHis tag at the C- terminus. |
|---|
| Purity | > 95% by SDS-PAGE. |
|---|
| Endotoxin | < 1 EU/μg of the protein by LAL method. |
|---|
| Formulation | Lyophilized from a 0.2 μm filtered solution of 20mM Hepes, 150mM NaCl, 1mM EDTA, pH 7.4.Contact us for customized product form or formulation. |
|---|
| Species | Human |
|---|
| Calculated MW | 57.3 kDa |
|---|
Background
Delta-like protein 1 (DLL1) is a type I transmembrane protein that belongs to the Delta/Serrate/Lag2 (DSL) family of Notch ligands. Mature human DLL1 consists of a 528 amino acid (aa) extracellular domain (ECD) with one DSL domain and eight EGF-like repeats, a 23 aa transmembrane segment, and a 155 aa cytoplasmic domain. Within the ECD, human DLL1 shares 91% aa sequence identity with mouse and rat DLL1. The residual membranebound portion of DLL1 can be cleave by presenilin-dependent γ -secretase, enabling the cytoplasmic domain to migrate to the nucleus. DLL1 localizes to adherens junctions on neuronal processes through its association with the scaffolding protein MAGI1. DLL1 is widely expressed, and it plays an important role in embryonic somite formation, cochlear hair cell differentiation, plus B and T lymphocyte differentiation. The upregulation of DLL1 in arterial endothelial cells following injury or angiogenic stimulation is central to postnatal arteriogenesis. DLL1 is also overexpressed in cervical carcinoma and glioma and contributes to tumor progression.
Product information
| Synonym | DLL1; DELTA1; DL1; Delta |
|---|
| Expression Host | HEK293 cells |
|---|
| Tag | C-His |
|---|
| Swiss-Prot | |
|---|
| Gene ID | |
|---|
Usage guide
| Storage | Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt.
After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week. |
|---|
| Reconstitution | Centrifuge the tube before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles. |
|---|
* For research use only. Not for therapeutic or diagnostic purposes.
